Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of botulinum toxin (most commonly type A) and a corticosteroid (corticoid). Botulinum toxin is a neurotoxin protein that inhibits acetylcholine release at neuromuscular junctions, leading to temporary muscle paralysis or relaxation. It is widely used for conditions such as dystonia, spasticity, chronic migraine, hyperhidrosis, and cosmetic indications like wrinkle reduction[1][6][7][8]. Corticosteroids are anti-inflammatory agents that suppress immune responses and reduce inflammation in various tissues. The combination of botulinum toxin type A with a corticosteroid has been studied primarily for the treatment of keloids and hypertrophic scars. Clinical evidence suggests this combination provides superior outcomes compared to corticosteroids alone in reducing scar thickness, pain, itching, and improving patient satisfaction[2]. The mechanism involves both the inhibition of fibroblast proliferation by the steroid and reduced muscle tension/contraction by the neurotoxin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum toxin + corticoid.